Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma by Jansen, Y. J. L. et al.
ORIGINAL ARTICLE
Discontinuation of anti-PD-1 antibody therapy in the
absence of disease progression or treatment limiting
toxicity: clinical outcomes in advanced melanoma
Y. J. L. Jansen1*†, E. A. Rozeman2†, R. Mason3,4, S. M. Goldinger5,6, M. H. Geukes Foppen2, L. Hoejberg7,
H. Schmidt8, J. V. van Thienen2, J. B. A. G. Haanen2, L. Tiainen9, I. M. Svane10, S. Mäkelä11, T. Seremet1,
A. Arance12, R. Dummer6, L. Bastholt7, M. Nyakas13, O. Straume14, A. M. Menzies5,15,16, G. V. Long5,15,16,
V. Atkinson4,3, C. U. Blank2‡ & B. Neyns1‡
1Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussel, Belgium; 2Department of Medical Oncology, The Netherlands Cancer Institute,
Amsterdam, The Netherlands; 3Department of Medical Oncology, Princess Alexandra Hospital, Brisbane; 4Greenslope Oncology, Greenslope Private Hospital,
Brisbrane; 5Melanoma Institute Australia and The University of Syndey, Sydney, Australia; 6Department of Dermatology, University Hospital Zurich, Zurich,
Switzerland; 7Department of Oncology, Odense University Hospital, Odense; 8Department of Oncology, Aarhus Universitet, Aarhus, Denmark; 9Department of
Oncology, Tampere University Hospital, Tampere, Finland; 10Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; 11Department of
Oncology, University of Helsinki, Helsinki, Finland; 12Department of Medical Oncology, Hospital Clı́nic Barcelona, Barcelona, Spain; 13Department of Clinical Cancer
Research, Oslo University Hospital, Oslo; 14Department of Oncology, Universitetet Bergen, Bergen, Norway; 15Department of Medical Oncology, Northern Sydney
Cancer Centre, Royal North Shore Hospital, Sydney; 16Department of Medical Oncology, Mater Hospital, Sydney, Australia
*Correspondence to: Dr Yanina J. L. Jansen, Department of Medical Oncology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussel, Belgium. Tel: þ32-24-77-60-40;
Fax: þ32-24-77-62-10; E-mail: Yanina.Jansen@uzbrussel.be
†These authors contributed equally as first authors.
‡Both authors share the senior authorship.
Note: This study was previously presented at the 2017 ASCO annual meeting, 2017 SMR meeting and 2018 EORTC melanoma work group.
Background: Programmed cell death protein 1 (PD-1) blocking monoclonal antibodies improve the overall survival of patients
with advanced melanoma but the optimal duration of treatment has not been established.
Patients and Methods: This academic real-world cohort study investigated the outcome of 185 advanced melanoma patients
who electively discontinued anti-PD-1 therapy with pembrolizumab (N¼ 167) or nivolumab (N¼ 18) in the absence of disease
progression (PD) or treatment limiting toxicity (TLT) at 14 medical centres across Europe and Australia.
Results: Median time on treatment was 12 months (range 0.7–43). The best objective tumour response at the time of
treatment discontinuation was complete response (CR) in 117 (63%) patients, partial response (PR) in 44 (24%) patients and
stable disease (SD) in 16 (9%) patients; 8 (4%) patients had no evaluable disease (NE). After a median follow-up of 18 months
(range 0.7–48) after treatment discontinuation, 78% of patients remained free of progression. Median time to progression was
12 months (range 2–23). PD was less frequent in patients with CR (14%) compared with patients with PR (32%) and SD (50%). Six
out of 19 (32%) patients who were retreated with an anti-PD-1 at the time of PD obtained a new antitumour response.
Conclusions: In this real-world cohort of advanced melanoma patients discontinuing anti-PD-1 therapy in the absence of TLT or
PD, the duration of anti-PD-1 therapy was shorter when compared with clinical trials. In patients obtaining a CR, and being treated
for>6 months, the risk of relapse after treatment discontinuation was low. Patients achieving a PR or SD as best tumour response
were at higher risk for progression after discontinuing therapy, and defining optimal treatment duration in such patients deserves
further study. Retreatment with an anti-PD-1 at the time of progression may lead to renewed antitumour activity in some patients.
Clinical trial registration: NCT02673970 (https://clinicaltrials.gov/ct2/show/NCT02673970?cond¼melanoma&cntry¼BE&
city¼Jette&rank¼3)
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Introduction
Blockade of the programmed cell death protein 1 (PD-1) cell sur-
face receptor relicenses antitumour T-cell activity in a tumour
microenvironment with expression of the programmed death-
ligand 1 (PD-L1) on tumour and/or other tumour infiltrating cells
[1, 2]. The PD-1 blocking monoclonal antibodies pembrolizumab
and nivolumab demonstrated overall survival (OS) benefit when
compared with ipilimumab or dacarbazine in patients with
advanced melanoma [3–5]. One- and two-year survival rates were
in the order of 70% (68%–74%) and 57% (55%–59%), respectively
[3, 6].
Optimal duration of anti-PD-1 therapy has not been estab-
lished. Within most clinical trials, patients could continue ther-
apy until progressive disease (PD) or treatment limiting toxicity
(TLT). In an early phase I trial with nivolumab, 12 (71%) of 17
patients experienced ongoing antitumour responses after treat-
ment cessation for reasons other than PD [7]. In the subgroup of
67 patients who stopped pembrolizumab treatment after obtain-
ing a complete response (CR) in the KEYNOTE-001 trial, the
24-month disease-free survival from time of CR was 89.9% [8].
In the phase III KEYNOTE-006 trial, 103 patients discontinued
pembrolizumab after the foreseen maximum duration of
24 months of which, 19 (18%) patients developed PD after a me-
dian follow-up of 20 months [9]. Notably, four (50%) responses
were observed among eight patients retreated with anti-PD-1
therapy.
Previously we reported the outcome of advanced melanoma
patients treated with PD-1 therapy outside of an interventional
clinical trial [10]. In this cohort, a subgroup of patients electively
stopped therapy in the absence of PD or TLT. We expanded this
cohort with additional patients from sites in Switzerland and




Clinical data from 803 unselected patients (cohort 1) with advanced mel-
anoma treated with anti-PD-1 monotherapy in 12 sites across Europe
and Australia were collected and pooled for analysis. Patients received
pembrolizumab or nivolumab in an expanded access programme or
according to the label after approval. Out of this cohort all patients that
discontinued therapy upon a joint-decision by the patient and the treat-
ing physician in the absence of PD or TLT (¼elective discontinuation)
were identified. An additional cohort (cohort 2) of patients that electively
stopped anti-PD-1 at two additional sites in Australia and Switzerland
was included in this analysis. Baseline characteristics, treatment dispos-
ition, tumour responses (according to immune related response criteria
[irRC]), progression-free survival (PFS) and OS were collected based on
the assessments made by the investigators.
In part, data were collected prospectively following written informed
consent of an institutional medical ethics committee approved form (UZ
Brussels and MIA) or by retrospective collection of data following ap-
proval of the institutional MEC (all other centres).
Statistical analysis
Descriptive statistics were used to report the baseline characteristics of
the study population. Logistic regression analysis and chi-square test
were used to identify potential predictive biomarkers for treatment
discontinuation.
Time on treatment was calculated as the time between the date of the
first administration of anti-PD-1 therapy and the date of the last adminis-
tration. Follow-up and PFS after elective treatment discontinuation were
calculated from the date of the last cycle to the date of PD or last follow-
up. OS was calculated from start of anti-PD-1 therapy to date of death or
last follow-up. PFS and OS for the whole population and subgroups
(according to best objective response [BOR] and duration of therapy)
were estimated using the Kaplan–Meier method and compared using
log-rank tests. Cox proportional hazard regression models were applied
to analyse associations between clinical characteristics and risks for PD.
Analyses were carried out using SPSS 25 (IBM).
Results
Baseline patient characteristics
We identified 185 advanced melanoma patients (cohort 1: 150
patients [supplementary Figure S1, available at Annals of
Oncology online] and cohort 2: 35 patients) who electively
stopped anti-PD-1 therapy (pembrolizumab [N¼ 167] or nivo-
lumab [N¼ 18]) (supplementary Table S1, available at Annals of
Oncology online) in the absence of PD or TLT. Anti-PD-1 therapy
was initiated between February 2013 and October 2016. Baseline
characteristics at treatment initiation are summarised in Table 1.
Anti-PD-1 therapy was administered as a first-line therapy in 80
(43%) patients. Prior therapies consisted of ipilimumab (91
[49%] patients) and BRAF-inhibitor (27 [15%] patients).
Ninety-eight (53%) patients were diagnosed with AJCC seventh
edition stage IV-M1c disease, 25 (13%) patients with brain meta-
stases, the majority had an ECOG performance status 1 (179
[97%] patients) and serum lactate dehydrogenase (LDH) was ele-
vated in 43 (23%) of the tested patients.
Treatment disposition and tumour response
At the data cut-off date on 10 May 2018, median follow-up after
treatment initiation was 32 months (range 3–60). BOR by irRC
on CT was CR in 117 (63%) patients, PR in 44 (24%) patients
and SD in 16 (9%) patients. Eight (4%) patients were non-
evaluable (NE, due to non-measurable disease according to
irRC). Median duration of anti-PD-1 therapy was 12 months
(range 0.7–43); only 26 (14%) patients were treated for
<6 months. Patients with CR, PR and SD as best response to
anti-PD1 were treated respectively for a median duration of
11 months (range 2–36), 15 months (range 2–43) and 14 months
(range 5–24) (Table 2).
Outcome after elective discontinuation of
anti-PD-1 treatment
After a median follow-up of 18 months (range 0.7–48) after treat-
ment discontinuation, 40 (22%) patients had progressed
(Table 2, Figure 1 and supplementary Figure S2, available at
Annals of Oncology online). Median PFS after discontinuation
has not been reached (Figure 1A). Median time to progression
was 12 months (range 2–23). The estimated 1-year and 2-year
PFS-rates after discontinuation were 90% (95% CI 85–94) and
71% (95% CI 63–79), respectively. BOR during initial anti-PD-1
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therapy in patients that developed PD was a CR in 16 (14% of all
patients with CR), PR in 14 (32% of all patients with PR), SD in 8
(50% of all patients with SD) and NE in 2 patients (25% of all
patients who were NE) (Table 2; Figures 2 and 3). Patients
obtaining a CR had a significant lower risk of PD compared with
patients obtaining a PR (P¼ 0.002; HR 2.99, 95% CI 1.45–6.16)
or maintaining SD (P< 0.001; HR 5.15, 95% CI 2.19–12.09)
(supplementary Table S2, available at Annals of Oncology online).
Estimated median PFS after discontinuation had not been
reached in patients with a CR, PR or NE and was 16 months
(range 13–18) in patients with SD (Figure 1B, supplementary
Table S2, available at Annals of Oncology online). Median PFS
after discontinuation was not reached in any of the subgroups
stratified according to treatment duration and no significant dif-
ference in PFS was found between these groups (Figure 1C, sup-
plementary Table S3, available at Annals of Oncology online).
Multivariable analysis including known prognostic clinical
characteristic (e.g. stage of disease and prior therapies) demon-
strated that patients with a CR had a lower risk of PD when com-
pared with patients with PR and SD and revealed no significant
association between risk of PD and treatment duration or clinical
characteristics (supplementary Table S4, available at Annals of
Oncology online). In the 117 patients with CR, patients who were
treated for<6 months had a significant higher risk of progression
(median PFS: 18.9 months [95% CI 15.8–22.3] versus not
reached for patients treated for >6 months, P< 0.05). There was
no difference in risk of PD between patients with CR treated for 6
Table 1. Baseline characteristics of patients who discontinued anti-PD-1
treatment in the absence of PD or TLT
Patient All patients
Characteristics N (%)













Occult primary 1 (0.5)
Unknown 28 (15)
Disease stage
Stage IIIc 10 (5)
Stage IV M1a 38 (21)
Stage IV M1b 37 (20)






















Line of therapy for anti-PD-1 mAb
First-line 80 (43)
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>ULN—1, 5 ULN 37 (20)
1.5 ULN—2 ULN 2 (1)













Data are presented as N (%) unless otherwise noted. According to AJCC
seventh edition. Abbreviations: PD-1, programmed cell death protein 1;
PD, disease progression; TLT, treatment limiting toxicity; mAb, monoclo-
nal antibody; ECOG PS, Eastern cooperative oncology group performance
status; CRP, C-reactive protein; ULN, upper limit of normal; LDH, lactate
dehydrogenase; ALC, absolute lymphocyte count; ANC, absolute neutro-
phil count.
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to 12, 12 to 18, 18 to 24 or >24 months (Figure 1D, supplemen-
tary Table S5, available at Annals of Oncology online).
Site of progression was known for 18 of the 40 (45%) progress-
ing patients; 11 (65%) patients had new lesions and 7 (35%)
patients progressed at a previously existing metastatic site. In 7
(35%) patients, the brain was the first site of progression (in 6
[86%] patients these were new lesions).
Outcome after retreatment with anti-PD-1 therapy
and alternative treatment-options
Nineteen (48%) of the 40 patients with PD were re-challenged
with pembrolizumab or nivolumab (Figures 2 and 3; Table 3).
Initial BOR of these 19 patients was a CR in 9 patients, PR in 6
and maintaining SD in 4 patients. BOR following retreatment
was CR in 2 (11%) patients (durable ongoing CR [10 and
21 months]), PR in 4 (21%) patients and SD in 5 (26%) patients.
Six (32%) patients did not benefit from retreatment. One (5%)
patient died before the first response evaluation and 1 (5%) pa-
tient has not yet been evaluated. Of the six objective responses
(two CR’s and two PR’s) documented after retreatment of anti-
PD-1 therapy, 5 (83%) responses were seen in patients obtaining
CR during their first exposure to anti-PD1 therapy (Table 3).
Twelve (30%) of the 40 patients with PD were salvaged with
loco-regional therapy (eight underwent surgery, three had radio-
therapy and one received electro chemotherapy) (Figure 3). Most
patients salvaged with surgery remained progression-free at data
cut-off; obtaining CR in 4 (50%), PR in 1 (13%), PD in 1 (13%)
and 2 (25%) patients were not yet evaluated. Three (8%) patients
were treated with BRAF-targeted therapy. In 6 (15%) no add-
itional treatment was started. One patient had a spontaneous de-
crease in the size of a brain lesion (4–2 mm) without active
treatment. Six (15%) patients died after developing PD, of which
4 (10%) died due to melanoma.
Discussion
Anti-PD-1 therapy is the most effective single-agent immuno-
therapy for patients with advanced melanoma [2, 3, 6]. In pro-
spective clinical trials, the duration of therapy has been arbitrarily
defined as up to the time of PD, TLT (CheckMate-067) or a max-
imum of 2 years (KEYNOTE-006) [3, 6]. Ongoing disease control
after cessation of anti-PD-1 therapy was observed in a substantial
number of patients discontinuing therapy due to TLT [11].
Likewise, a number of observations from phase I and phase III
clinical trials indicate that patients can experience ongoing bene-
fit after discontinuing therapy in the absence of PD or TLT [7–9].
Furthermore, in melanoma patients treated with ipilimumab
plus nivolumab, similar survival outcomes were reported for
patients that discontinued due to TLT and those who did not
[12]. Durable responses after short duration of therapy have also
been observed for other immunotherapies, including ipilimumab
mono-therapy, TIL therapy and high dose interleukin 2 [13, 14].
Our study is the first to report treatment duration and out-
come (including outcome after retreatment with anti-PD-1) after
elective treatment discontinuation in a large real-world cohort of
185 advanced melanoma patients. Treatment exposure was vari-
able and with a median of 1 year on treatment, considerably
shorter when compared with the maximum treatment duration
in the KEYNOTE-006 trial (2 years) [3, 6]. The conditions for
stopping anti-PD-1 therapy were not predefined or harmonised
among centres and were made at the discretion of the treating phys-
ician in agreement with the patient, reflecting both the patient’s
desire and physician’s acceptance to discontinue therapy.
Retrospectively, CR was a main driver for treatment discontinu-
ation and this subgroup had the shortest treatment exposure. A sig-
nificant number of patients stopped treatment despite persisting
radiological evidence of disease. Objective parameters not captured
during our study such as depth of response, durability of response
and the metabolic responses on FDG-PET scans are likely to have
contributed to the decision-making. The population of patients that
electively stopped therapy was characterised by a lower frequency of
BRAF V600 mutation, a better performance status, a lower tumour
stage and incidence of brain metastases, and lower frequency of ele-
vated CRP and LDH levels at baseline when compared with patients
that did not discontinue before PD or TLT (supplementary Tables
S6 and S7, available at Annals of Oncology online).
After a median follow-up of 18 months following treatment
discontinuation, 40 (22%) patients had developed PD which is a
comparable to the KEYNOTE-006 trial (18% progressed after
a median follow-up of 20 months) [9]. Our cohort includes a
higher number of patients (185 versus 103), and was
characterised by a higher percentage of patients with a CR (63%
versus 27%), but a lower percentage of patients receiving anti-
PD-1 as first-line therapy (43% versus 66%). Notably 50% had
prior ipilimumab, and 15% targeted therapy, however this did











Median time of follow-up
after discontinuation
N (%) N (%) months (range) months (range) months (range)
All 185 (100) 40 (22) 32 (3–60) 12 (0.7–43) 18 (0.7–48)
Complete response 117 (63) 16 (14) 32 (3–60) 11 (2–36) 20 (0.7–48)
Partial response 44 (24) 14 (32) 34 (7–53) 15 (1–43) 16 (1–31)
Stable disease 16 (9) 8 (50) 32 (14–44) 14 (6–24) 16 (3–26)
Non-evaluable disease 8 (4) 2 (25) 27 (13–41) 7 (0.7–12) 17 (11–29)
Abbreviations: PD-1, programmed cell death protein 1; PD, disease progression; TLT, treatment limiting toxicity.
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not affect the risk of disease progression. We observed that the
risk of PD following treatment discontinuation was significantly
associated with BOR, and significant lower in patients with a CR.
Among patients with a CR, the risk of progression was signifi-
cantly higher in the group treated for <6 months; however, this
association was not seen for the whole population (including the
smaller populations of patients with PR, SD or NE), and in
patients with CR treated for >6 months, we did not find an asso-
ciation between risk of PD and duration of therapy.
In our real-world retrospective cohort, patients with a PR who
discontinued anti-PD-1 therapy in the absence of TLT or PD
seemed to be at higher risk for subsequent PD compared with
those in the prospective KEYNOTE-006 study (32% versus 14%).
While inevitably enriching for patients who would have pro-
gressed on-therapy when evaluating a population with a shorter
exposure, and difference in baseline characteristics may be of in-
fluence, a negative effect of shorter treatment duration on PFS,
and perhaps also on OS, cannot be ruled out.
The retrospective nature and the lack of central radiology re-
view warrant a careful interpretation of our observations but they
clearly indicate that defining the optimal duration of treatment
with anti-PD-1 therapy deserves further investigation.
Continuing therapy means that patients remain at risk of treat-
ment related adverse events, which may affect quality of life.
Secondly, unnecessary continuation of therapy is associated with
a significant financial burden with drug costs, administration
infrastructure and out-of-pocket expenses to patients.
Data from randomised trials are needed to establish guidelines
for optimal treatment duration, especially in patients achieving a
PR or SD as best tumour response. Recently, it was shown that a
complete metabolic tumour response on FDG-PET/CT at 1-year
following initiation of anti-PD-1 may have greater utility than
CT response in predicting long-term PFS [15]. Other innovative
measures addressing the kinetics and depth of tumour response
(measurement of circulating tumour DNA [16]) as well as base-
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According to treatment duration (CR only)D
Figure 1. Kaplan–Meier probability curves for progression-free survival from discontinuation of anti-PD-1. Progression free survival from dis-
continuation of anti-PD-1 for the total cohort that discontinued in the absence of PD or TLT (A); according to best overall (B) and according
to time on anti-PD-1 therapy for the whole cohort (C) and only for patients with a CR (D). The hash marks designate patients who were cen-
sored at that time point. Abbreviations: PD-1, programmed cell death protein 1; BOR, best overall response; PD, progressive disease; TLT,
treatment limiting toxicity.
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Figure 2. Outcome of 185 patients discontinuing treatment according to BOR and outcome after PD-1 reintroduction. Of the 185 patients who
discontinued anti-PD-1, 40 patients experienced progressive disease. A PD-1 inhibitor was re-introduced in 19 patients leading to 6 renewed ob-
jective responses (32%, two patients with a CR [11%] and four patients with a PR [21%]). Abbreviations: PD-1, Programmed cell death protein 1; CR,
complete response; PR, partial response; SD, stable disease; NE, non-evaluable disease; PD, progressive disease; BOR, best objective response.
















Figure 3. Swimmer plot indicating time on anti-PD-1 treatment, progression-free survival, and overall survival of patients with progression
after discontinuation of anti-PD-1. Abbreviations: PD-1, Programmed cell death protein 1; BOR, best overall response; CR, complete response;
PR, partial response; SD, stable disease, NE, non-evaluable disease.
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e.g. gene expression signatures or mutational load [17], may be
able to define optimised individualised treatment schedules in
patients benefiting from anti-PD-1 therapy, especially in non-CR
patients. Our data can help guide the design of future prospective
clinical trials examining this important issue. Three investigator-
led clinical trials have already been initiated (STOP-GAP trial,
NCT02821013, SAFE-STOP NTR7502 and DANTE,
EDURACT2017-002435-42).
Although the number of patients being retreated at the time of
progression is relatively small (N¼ 19), our case series indicates, in
line with the data from the KEYNOTE-006 trial, that retreatment
can lead to renewed antitumour activity in a subset of patients after
a treatment break. Future prospective studies are needed to address
the efficacy of retreatment with anti-PD-1 therapy.
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